Search

Your search keyword '"Niemann, Carsten Utoft"' showing total 173 results
Start Over Author "Niemann, Carsten Utoft" Language english
173 results on '"Niemann, Carsten Utoft"'

4. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Author

Al-Sawaf, Othman, Robrecht, Sandra, Zhang, Can, Olivieri, Stefano, Chang, Yi Meng, Fink, Anna Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Kreuzer, Karl-Anton, Sivchev, Liliya, Niemann, Carsten Utoft, Schwarer, Anthony, Loscertales, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah, Manzoor, Beenish S., Jawaid, Dureshahwar, Emechebe, Nnadozie, Devine, Jacob, Boyer, Michelle, Runkel, Eva D., Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael, and Fischer, Kirsten

Published
2024
Full Text
View/download PDF

5. Deep immune cell phenotyping and induced immune cell responses at admission stratified by BMI in patients hospitalized with COVID-19: An observational multicenter cohort pilot study

Author

Sejdic, Adin, Hartling, Hans Jakob, Gitz Holler, Jon, Klingen Gjærde, Lars, Matovu Dungu, Arnold, Engel Møller, Maria Elizabeth, Svanberg Teglgaard, Rebecca, Utoft Niemann, Carsten Utoft, Brooks, Patrick Terrence, Mogensen, Trine H., Weis, Nina, Podlekareva, Daria, Baum Jørgensen, Marie Louise, Ortved Gang, Anne, Stampe Hersby, Ditte, Hald, Annemette, Dam Nielsen, Susanne, Lebech, Anne-Mette, Helleberg, Marie, Lundgren, Jens, Træholt Franck, Kristina, Fischer, Thea K., Barrella Harboe, Zitta, Marquart, Hanne Vibeke, Rye Ostrowski, Sisse, and Lindegaard, Birgitte

Published
2024
Full Text
View/download PDF

6. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Author

Langerbeins, Petra, Giza, Adam, Robrecht, Sandra, Cramer, Paula, von Tresckow, Julia, Al-Sawaf, Othman, Fink, Anna Maria, Fürstenau, Moritz, Kutsch, Nadine, Simon, Florian, Goede, Valentin, Hoechstetter, Manuela, Niemann, Carsten Utoft, da Cunha-Bang, Caspar, Kater, Arnon, Dubois, Julie, Gregor, Michael, Staber, Philipp Bernhard, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Eichhorst, Barbara, Fischer, Kirsten, and Hallek, Michael

Published
2024
Full Text
View/download PDF

7. Author Correction: Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients

Author

Svanberg, Rebecka, MacPherson, Cameron, Zucco, Adrian, Agius, Rudi, Faitova, Tereza, Andersen, Michael Asger, da Cunha-Bang, Caspar, Gjærde, Lars Klingen, Møller, Maria Elizabeth Engel, Brooks, Patrick Terrence, Lindegaard, Birgitte, Sejdic, Adin, Harboe, Zitta Barrella, Gang, Anne Ortved, Hersby, Ditte Stampe, Brieghel, Christian, Nielsen, Susanne Dam, Podlekareva, Daria, Hald, Annemette, Bay, Jakob Thaning, Marquart, Hanne, Lundgren, Jens, Lebech, Anne-Mette, Helleberg, Marie, Niemann, Carsten Utoft, and Ostrowski, Sisse Rye

Published
2023
Full Text
View/download PDF

8. Risk of haematologic cancers among individuals tested for Borrelia burgdorferi antibodies, and Borrelia burgdorferi seropositive individuals: a nationwide population-based matched cohort study

Author

Tetens, Malte M., Omland, Lars Haukali, Dessau, Ram, Ellermann-Eriksen, Svend, Andersen, Nanna S., Jørgensen, Charlotte Sværke, Østergaard, Christian, Bodilsen, Jacob, Søgaard, Kirstine K., Bangsborg, Jette, Nielsen, Alex Christian, Møller, Jens Kjølseth, Chen, Ming, Niemann, Carsten Utoft, Lebech, Anne-Mette, and Obel, Niels

Published
2024
Full Text
View/download PDF

15. Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients

Author

Svanberg, Rebecka, MacPherson, Cameron, Zucco, Adrian, Agius, Rudi, Faitova, Tereza, Andersen, Michael Asger, da Cunha-Bang, Caspar, Gjærde, Lars Klingen, Møller, Maria Elizabeth Engel, Brooks, Patrick Terrence, Lindegaard, Birgitte, Sejdic, Adin, Gang, Anne Ortved, Hersby, Ditte Stampe, Brieghel, Christian, Nielsen, Susanne Dam, Podlekareva, Daria, Hald, Annemette, Bay, Jakob Thaning, Marquart, Hanne, Lundgren, Jens, Lebech, Anne-Mette, Helleberg, Marie, Niemann, Carsten Utoft, and Ostrowski, Sisse Rye

Published
2022
Full Text
View/download PDF

17. Complex Relationships between Diagnostics and Survival in Chronic Lymphocytic Leukemia in Denmark, Finland, Norway, and Sweden.

Author

Hemminki, Kari, Zitricky, Frantisek, Försti, Asta, Tapaninen, Tuija, Hemminki, Akseli, Juliusson, Gunnar, and Niemann, Carsten Utoft

Subjects
CHRONIC lymphocytic leukemia diagnosis, CHRONIC lymphocytic leukemia, MORTALITY, RESEARCH funding, SEX distribution, AGE distribution, DESCRIPTIVE statistics, CHRONIC diseases
Abstract

Simple Summary: Chronic lymphocytic leukemia (CLL) is a common leukemia characterized by an accumulation of lymphocytes in the blood and lymphoid organs. Disease presentation is highly variable as many patients do not initially require any treatment, and a watch and wait strategy remains the standard of care for up to 50% of patients. However, for those with a progressive disease, chemotherapy is the standard treatment and has improved over the years, increasing the survival of patients. We analyze here age-specific relative survival trends in CLL through 50 years up to 2020s in Denmark, Finland, Norway, and Sweden using the NORDCAN database. The large age-specific survival differences in 1972–76 almost disappeared by 2017–21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80–89-years, survival improved later, reaching 90% in Denmark and less in the other countries. Survival in Denmark is probably among the best in the world, which could be achieved by boosting survival even among the oldest patients. Most Nordic survival rates were better than those in the USA. Background: Chronic lymphocytic leukemia (CLL) is a common hematological malignancy with highly variable clinical presentation. Many patients never require any treatment but for the others, chemotherapy, immunochemotherapy, and newer targeted therapies have changed the treatment landscape. Diagnostic age influences the applied treatment, and we thus wanted to analyze age-specific survival trends through 50 years up to 2020s. Methods: We used 1- and 5-year relative survival from the NORDCAN database, with data from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE). Because of the variable presentation of CLL, we also considered incidence and mortality trends. For comparison, US SEER data were used. Results: The large age-specific survival differences in 1972–76 almost disappeared by 2017–21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80–89 years, survival reached 90% in DK and SE women, 80% in NO and SE men, but only 50% in FI. DK 5-year overall survival for men was 92.4%, and for women, it was 96.3%. These survival figures were higher than age-group-specific US survival data. Conclusions: The DK data are probably global top figures for national survival which could be achieved by boosting survival even among the oldest patients. The qualification to these figures and international comparisons is that survival needs to be considered in terms of incidence, which is high in DK and NO. Low survival of the FI 80–89-year-old patients, even in the first year after diagnosis, may suggest delayed diagnosis, which should call for a closer national scrutiny. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

Author

Langerbeins, Petra, Giza, Adam, Robrecht, Sandra, Cramer, Paula, von Tresckow, Julia, Al‐Sawaf, Othman, Fink, Anna Maria, Fürstenau, Moritz, Kater, Arnon P., van der Spek, Ellen, Niemann, Carsten Utoft, da Cunha‐Bang, Caspar, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Fischer, Kirsten, Hallek, Michael, and Eichhorst, Barbara

Published
2024
Full Text
View/download PDF

22. Immune cell populations and induced immune responses at admission in patients hospitalized with vaccine breakthrough SARS-CoV-2 infections.

Author

Sejdic, Adin, Hartling, Hans Jakob, Holler, Jon Gitz, Gjærde, Lars Klingen, Lindegaard, Birgitte, Dungu, Arnold Matovu, Gnesin, Filip, Møller, Maria Elizabeth Engel, Teglgaard, Rebecca Svanberg, Niemann, Carsten Utoft, Brooks, Patrick Terrence, Jørgensen, Charlotte Sværke, Franck, Kristina Træholt, Fischer, Thea K., Marquart, Hanne Vibeke, Harboe, Zitta Barrella, and Ostrowski, Sisse Rye

Subjects
BREAKTHROUGH infections, CELL populations, IMMUNE response, HOSPITAL admission & discharge, COVID-19
Abstract

Background: Vaccine breakthrough SARS-CoV-2 infections are common and of clinical and public health concern. However, little is known about the immunological characteristics of patients hospitalized due to these infections. We aimed to investigate and compare immune cell subpopulations and induced immune responses in vaccinated and non-vaccinated patients hospitalized with severe COVID-19. Methods: A nested case-control study on adults (≥ 18 years) who received at least two doses of a mRNA-COVID-19 vaccine and were hospitalized with SARSCoV-2 breakthrough infections and severe COVID-19 between January 7, 2021, and February 1, 2022, were eligible for inclusion. Age- and sex-matched nonvaccinated controls were identified. Immunophenotyping was performed using a custom-designed 10-color flow cytometry prefabricated freeze-dried antibody panel (DuraClone, Beckman Coulter (BC), Brea, Calif). TruCulture (Myriad RBM, Austin, USA) was used to assess induced immune response in whole blood, revealing different critical signaling pathways as a proxy for immune function. All samples were obtained within 48 hours of admission. Results: In total, 20 hospitalized patients with severe COVID-19 and a breakthrough SARS-CoV-2 infection were included, ten vaccinated and ten non-vaccinated patients. Vaccinated patients had lower concentrations of CD19 B cells (p = 0.035), naïve CD4 T cells (p = 0.015), a higher proportion of γδ1 T cells (p = 0.019), and higher unstimulated immune cell release of IL-10 (p = 0.015). Conclusion: We observed immunological differences between vaccinated and non-vaccinated patients hospitalized due to severe COVID-19 that indicate that vaccinated patients had lower B cell concentrations, lower concentrations of CD4 naïve T cells, a skewed gamma-delta V1/V2 ratio, and an exaggerated IL-10 response at admission. These results could indicate a suboptimal immune response involved in SARS-CoV-2 breakthrough infections that cause severe COVID-19 in vaccinated adults. However, the sample size was small, and further research is needed to confirm these results. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Clonal hematopoiesis and COVID‐19 hospitalization in Danish adults.

Author

Sequeros, Celia Burgos, Tulstrup, Morten, Bliddal, Sofie, Sørensen, Karina Meden, Nissen, Ioanna, Rezahosseini, Omid, Brooks, Patrick Terrence, Feenstra, Bjarke, Gang, Anne Ortved, Geller, Frank, Hald, Annemette, Harboe, Zitta Barrella, Helleberg, Marie, Jespersen, Jakob S., Lebech, Anne‐Mette, Lindegaard, Birgitte, Mogensen, Trine H., Møller, Maria Elizabeth Engel, Nielsen, Claus Henrik, and Niemann, Carsten Utoft

Published
2024
Full Text
View/download PDF

26. Immune Dysfunction and Infection – Interaction between CLL and Treatment: A Reflection on Current Treatment Paradigms and Unmet Needs.

Author

Gargiulo, Ernesto, Teglgaard, Rebecca Svanberg, Faitová, Tereza, and Niemann, Carsten Utoft

Abstract

Background: Chronic lymphocytic leukemia (CLL) is a hematological malignancy characterized by immune dysfunction, which significantly contributes to increased morbidity and mortality due to infections. Summary: Advancement in therapeutic strategies based on combination chemoimmunotherapy and targeted treatment have increased life expectancy for patients affected by CLL. However, mortality and morbidity due to infection showed no improvement over the last decades. Although therapy options are highly efficient in targeting leukemic cells, several studies highlighted the interactions of different treatments with the tumor microenvironment immune components, significantly impacting their clinical efficacy and fostering increased risk of infections. Key Messages: Given the profound immune dysfunction caused by CLL itself, treatment can thus represent a double-edged sword. Thus, it is essential to increase our understanding and awareness on how conventional therapies affect the disease-microenvironment-infection axis to ensure the best personalized strategy for each patient. This requires careful consideration of the advantages and disadvantages of efficient treatments, whether chemoimmunotherapy or targeted combinations, leading to risk of infectious complications. To this regard, our machine learning-based algorithm CLL Treatment-Infection Model, currently implemented into the local electronic health record system for Eastern Denmark, aims at early identification of patients at high risk of serious infections (PreVent-ACaLL; NCT03868722). We here review strategies for management of immune dysfunction and infections in CLL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Author

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M. N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjørn, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C, Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

31. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, Scarfò, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Mónica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuéllar-García, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet Palomanes, Juan, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Miras Calvo, Fatima, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Raa, Doreen te, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca Ciocan, Oana, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van Der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yáñez, Lucrecia, Yassin, Mohamed A, Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2022
Full Text
View/download PDF

32. Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Author

Tausch, Eugen, Schneider, Christof, Furstenau, Moritz, Robrecht, Sandra, Yosifov, Deyan Yordanov, Mertens, Daniel, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Poulsen, Christian Bjørn, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Noesslinger, Thomas, Baumann, Michael, Wendtner, Clemens-Martin, Eldering, Eric, Kreuzer, Karl-Anton, Ritgen, Matthias, Fink, Anna-Maria, Fischer, Kirsten, Kater, Arnon P., Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, and Stilgenbauer, Stephan

Published
2022
Full Text
View/download PDF

33. Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

Author

Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, Von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Furstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Dürig, Jan, Böttcher, Sebastian, Niemann, Carsten Utoft, Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Döhner, Hartmut, Hallek, Michael, Eichhorst, Barbara, and Stilgenbauer, Stephan

Published
2022
Full Text
View/download PDF

34. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.

Author

Del Giudice, Ilaria, Cappelli, Luca Vincenzo, Delgado, Julio, Niemann, Carsten Utoft, Andersen, Michael Asger, Rotbain, Emelie Hamotal Curovic, Aarup, Kathrine, Walewska, Renata, Visentin, Andrea, Deodato, Marina, Frustaci, Anna Maria, Cavalloni, Chiara, Gentile, Massimo, Yassin, Mohamed A., Lad, Deepesh, Scarfò, Lydia, Flogegard, Max, Mattsson, Mattias, Raponi, Sara, and Ilari, Caterina

Subjects
LYMPHOCYTIC leukemia, LITERATURE reviews, CHRONIC leukemia, GASTROINTESTINAL stromal tumors, RICHTER syndrome
Abstract

Thirty-seven patients were alive at the last follow-up, 13 had died (two dementia-related causes, one pneumonia, one warfarin-related bleeding, one ovarian cancer, eight because of unknown causes); no patient died due to CLL progression. Of the five patients initially categorized as in partial SR, three have subsequently converted to SR, one remains in partial SR and in one patient who achieved a partial SR after 19 years from diagnosis the lymphocyte count started to increase five years later. Of the four patients in stage B/II at diagnosis, two converted to A/0 and one to A/I. In the five patients with a partial SR, the median lymphocyte count at regression was 6.3 × 10 SP 9 sp /L, with a median lymphocyte decrease of 75.1% (69-89%), and at the last follow-up a median lymphocyte count of 5.6 × 10 SP 9 sp /L (5.3-11.8) (Figure 1). [Extracted from the article]

Published
2023
Full Text
View/download PDF

36. Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.

Author

Klausen, Uffe, Grauslund, Jacob Handlos, Dahlager Jørgensen, Nicolai Grønne, Ahmad, Shamaila Munir, Jonassen, Merete, Weis-Banke, Stine Emilie, Martinenaite, Evelina, Pedersen, Lone Bredo, Lisle, Thomas Landkildehus, Gang, Anne Ortved, Enggaard, Lisbeth, Hansen, Morten, Holmström, Morten Orebo, Met, Özcan, Svane, Inge Marie, Niemann, Carsten Utoft, Pedersen, Lars Møller, and Andersen, Mads Hald

Subjects
CHRONIC lymphocytic leukemia, IMMUNOGLOBULIN heavy chains, CHRONIC leukemia, VACCINE immunogenicity, LYMPHOCYTE count, VACCINE effectiveness
Abstract

Chronic lymphocytic leukemia (CLL) patients with unmutated immunoglobulin heavy chain (IgHV) are at risk of early disease progression compared to patients with mutated IgHV. As a preventive strategy, we treated 19 previously untreated CLL patients with unmutated IgHV in a phase 1/2 trial (clinicaltrials.gov, NCT03939234) exploring the efficacy and toxicity of a therapeutic cancer vaccine containing peptides derived from programmed death ligand 1 (PD-L1) and ligand 2 (PD-L2), hoping to restore immunological control of the disease. According to the International Workshop on Chronic lymphocytic Leukemia (iwCLL) response criteria, no patients obtained a response; however, during follow-up, one patient had complete normalization of the peripheral lymphocyte count and remained in biochemical remission after a follow-up time of 15 months. At the end of treatment, one patient had progressed, and 17 patients had stable disease. During follow-up with a median time of 23.5 months since inclusion, seven patients had progressed, and eight patients had stable disease. The median time to first treatment (TTFT) from diagnosis was 90.3 months with a median follow-up time of 50.1 months. This apparent favorable outcome in TTFT needs to be investigated in a randomized setting, as our population may have been biased. More than 80% of patients obtained vaccine-specific immune responses, confirming the immunogenicity of the vaccine. The vaccine was generally well tolerated with only grade I–II adverse events. Although there were some signs of clinical effects, the vaccine seems to be insufficient as monotherapy in CLL, possibly due to a high tumor burden. The efficacy of the vaccine should preferably be tested in combination with novel targeted therapies or as a consolidating treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Author

Simon, Florian, Ligtvoet, Rudy, Robrecht, Sandra, Cramer, Paula, Kutsch, Nadine, Furstenau, Moritz, Goede, Valentin, Von Tresckow, Julia, Langerbeins, Petra, Fink, Anna-Maria, Huber, Henriette, Tausch, Eugen, Schneider, Christof, Wendtner, Clemens-Martin, Ritgen, Matthias, Dreyling, Martin, Müller, Lothar, Jacobasch, Lutz, Heinz, Werner, Vehling-Kaiser, Ursula, Sivcheva, Liliya, Böttcher, Sebastian, Dreger, Peter, Illmer, Thomas, Gregor, Michael, Staber, Philipp Bernhard, Stilgenbauer, Stephan, Niemann, Carsten Utoft, Kater, Arnon P., Fischer, Kirsten, Eichhorst, Barbara F., Hallek, Michael, and Al-Sawaf, Othman

Published
2023
Full Text
View/download PDF

41. First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Author

Moreno, Carol, Munir, Talha, Owen, Carolyn, Follows, George, Hernandez Rivas, Jose-Angel, Benjamini, Ohad, Janssens, Ann, Levin, Mark-David, Robak, Tadeusz, Simkovic, Martin, Voloshin, Sergey, Vorobyev, Vladimir I., Yagci, Munci, Ysebaert, Loic, Qi, Qianya, Smith, Emma, Srinivasan, Srimathi, Schuier, Natasha, Baeten, Kurt, Caces, Donne Bennett, Niemann, Carsten Utoft, and Kater, Arnon P.

Published
2023
Full Text
View/download PDF

42. The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Author

Al-Sawaf, Othman, Fürstenau, Moritz, Giza, Adam, Robrecht, Sandra, Von Tresckow, Julia, Fink, Anna Maria, Simon, Florian, Tausch, Eugen, Schneider, Christof, Sivcheva, Liliya, Schwarer, Anthony, Loscertales, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah R., Juliusson, Gunnar, Da Cunha-Bang, Caspar, Illmer, Thomas, Gregor, Michael, Thornton, Patrick, Janssens, Ann, Tadmor, Tamar, Lindström, Vesa, Staber, Philipp Bernhard, Levin, Mark-David, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Ritgen, Matthias, Stilgenbauer, Stephan, Kater, Arnon P., Niemann, Carsten Utoft, Fischer, Kirsten, Eichhorst, Barbara F., and Hallek, Michael

Published
2023
Full Text
View/download PDF

43. Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Author

Pavlova, Sarka, Malcikova, Jitka, Radova, Lenka, Bonfiglio, Silvia, Cowland, Jack B., Brieghel, Christian, Andersen, Mette Klarskov, Karypidou, Maria, Biderman, Bella V, Doubek, Michael, Lazarian, Gregory, Rapado, Inmaculada, Vynck, Matthijs, Porret, Naomi, Andres, Martin, Rosenberg, Dina, Sahar, Dvora, Martinez-Laperche, Carolina, Borde, Ismael Buño, Hindley, Andrew, Sánchez, Julio Bravo, García-Marco, José, Serrano, Alicia, Ferrer Lores, Blanca, Fernández-Rodriguez, Concepción, Bellosillo, Beatriz, Stilgenbauer, Stephan, Tausch, Eugen, Nikdin, Hero, Quinn, Fiona, Atkinson, Emer, Van De Corput, Lisette, Yildiz, Cafer, Bilbao, Cristina, Florido, Yanira, Thiede, Christian, Schuster, Caroline, Stoj, Anastazja, Czekalska, Sylwia, Chatzidimitriou, Anastasia, Laidou, Stamatia, Bidet, Audrey, Dussiau, Charles, Nollet, Friedel, Piras, Giovanna, Borosova, Tereza, Kurucova, Terezia, Monne, Maria, Smirnova, Svetlana, Nikitin, Evgeny, Sloma, Ivan, Delfau, Marie-Helene, Largeaud, Laetitia, Ysebaert, Loic, Valk, Peter J. M., Christian, Amy, Walewska, Renata, Sebastião, Marta, da Silva, Maria Gomes, Galieni, Piero, Angelini, Mario, Rossi, Davide, Spina, Valeria, Matos, Sónia, Martins, Vânia, Donaldson, David, Stoklosa, Tomasz, Pepek, Monika, Baliakas, Panagiotis, Andreu, Rafa, Luna, Irene, Kahre, Tiina, Murumets, Ülle, Laird, Sophie, Ward, Daniel, Alcoceba, Miguel, Balanzategui, Ana, Scarfo, Lydia, Gandini, Francesca, Zapparoli, Ettore, Blanco, Adoracion, Costa, Pau Abrisqueta, Rodriguez, Ana E., Benito Sanchez, Maria Rocio, Davi, Frédéric, Bravetti, Clothilde, Gameiro, Paula, Martinez-Lopez, Joaquin, Tazon, Barbara, Baran-Marszak, Fanny, Davies, Zadie, Caterwood, Mark, Sudarikov, Andrey B, Rosenquist, Richard, Niemann, Carsten Utoft, Stamatopoulos, Kostas, Ghia, Paolo, and Pospisilova, Sarka

Published
2023
Full Text
View/download PDF

45. An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Author

Wang, Yucai, Larson, Melissa C., Farooq, Umar, Ekberg, Sara, Ekstroem Smedby, Karin, Simonsen, Mikkel Runason, Niemann, Carsten Utoft, Zhao, Eric J., Gerrie, Alina S., Switchenko, Jeffrey M., Bond, David A., Bachanova, Veronika, Barta, Stefan K., Hill, Brian T., Martin, Peter, Danilov, Alexey, Grover, Natalie S., Karmali, Reem, Ghosh, Nilanjan, Fenske, Timothy S., Kahl, Brad S., Albertsson-Lindblad, Alexandra, Glimelius, Ingrid Cecilia, Ludvigsen Al-Mashhadi, Ahmed, Stauffer Larsen, Thomas, Maddocks, Kami J., Link, Brian K., Paludo, Jonas, Nowakowski, Grzegorz S., Habermann, Thomas M., Maurer, Matthew J., Villa, Diego, Cohen, Jonathon B., El-Galaly, Tarec Christoffer Christoffer, Jerkeman, Mats, and Cerhan, James R.

Published
2023
Full Text
View/download PDF

46. Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Author

Al-Sawaf, Othman, Ligtvoet, Rudy, Robrecht, Sandra, Stumpf, Janina, Fink, Anna Maria, Tausch, Eugen, Schneider, Christof, Böttcher, Sebastian, Mikusko, Martin, Ritgen, Matthias, Schetelig, Johannes, Von Tresckow, Julia, Vehling-Kaiser, Ursula, Wendtner, Clemens-Martin, Fischer, Kirsten, Kreuzer, Karl Anton, Stilgenbauer, Stephan, Staber, Philipp Bernhard, Niemann, Carsten Utoft, Hallek, Michael, and Eichhorst, Barbara F.

Published
2023
Full Text
View/download PDF

47. First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Author

Fürstenau, Moritz, Ritgen, Matthias, Robrecht, Sandra, Von Tresckow, Julia, Zhang, Can, Schilhabel, Anke, Gregor, Michael, Thornton, Patrick, Staber, Philipp Bernhard, Tadmor, Tamar, Lindström, Vesa, Juliusson, Gunnar, Janssens, Ann, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Goldschmidt, Neta, Vandenberghe, Elisabeth, Rossi, Davide, Benz, Rudolf A., Heintel, Daniel, Poulsen, Christian Bjørn, Christiansen, Ilse, Frederiksen, Henrik, Enggaard, Lisbeth, Posthuma, Eduardus, Issa, Djamila, Visser, Hein, Bellido, Mar, Kutsch, Nadine, Dürig, Jan, Stehle, Alexander, Voehringer, Matthias C., Böttcher, Sebastian, Schulte, Clemens, Simon, Florian, Fink, Anna-Maria, Fischer, Kirsten, Holmes, Emily, Kreuzer, Karl-Anton, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Hallek, Michael, Kater, Arnon P., Niemann, Carsten Utoft, and Eichhorst, Barbara F.

Published
2023
Full Text
View/download PDF

49. Artificial intelligence models in chronic lymphocytic leukemia – recommendations toward state-of-the-art.

Author

Agius, Rudi, Parviz, Mehdi, and Niemann, Carsten Utoft

Subjects
CHRONIC lymphocytic leukemia, ARTIFICIAL intelligence, MACHINE learning, PROGNOSIS, PROGNOSTIC models
Abstract

Artificial intelligence (AI), machine learning and predictive modeling are becoming enabling technologies in many day-to-day applications. Translation of these advances to the patient's bedside for AI assisted interventions is not yet the norm. With specific emphasis on CLL, here, we review the progress of prognostic models in hematology and highlight sources of stagnation that may be limiting significant improvements in prognostication in the near future. We discuss issues related to performance, trust, modeling simplicity, and prognostic marker robustness and find that the major limiting factor in progressing toward state-of-the-art prognostication within the hematological community, is not the lack of able AI algorithms but rather, the lack of their adoption. Current models in CLL still deal with the 'average' patient while the use of patient-centric approaches remains absent. Using lessons from research areas where machine learning has become an enabling technology, we derive recommendations and propose methods for achieving state-of-the-art predictions in modeling health data, that can be readily adopted by the CLL modeling community. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results